1. At a Glance – The Smallcap Pharma That’s Either Undervalued… Or Under Pressure
Coral Laboratories Ltd is currently trading at ₹424, with a market cap of just ₹151 crore. The stock has corrected -12.6% in 3 months and a painful -45.1% in one year. That’s not a dip — that’s a cliff.
Yet here’s the twist.
The company trades at a P/E of 10.6, way below the pharma industry average of 28.2. It is sitting at 0.71x book value, has almost zero debt (₹0.88 crore), and boasts an interest coverage ratio of 96.6. Basically, debt doesn’t scare them — revenue decline does.
Latest Q3 FY26 numbers?
- Sales: ₹21.56 crore
- PAT: ₹2.78 crore
- Profit down 54.7% YoY
- Sales down 6.22% YoY
EPS for Q3: ₹7.78.
Annualised EPS (Q3 rule applied: average Q1, Q2, Q3 × 4) = ₹41.65.
The company manufactures pharma formulations and exports to countries like Ethiopia, Sudan, Nigeria, Kazakhstan and more.
So the question is simple:
Is this a boring export-focused pharma quietly compounding… or a small player losing steam?
Let’s dissect.
2. Introduction – The Underrated Pharma Exporter From Daman & Dehradun
Incorporated in 1994, Coral Laboratories Ltd is not a flashy biotech company making AI-designed molecules. It is a classic generics manufacturer.
The kind that doesn’t make headlines — it makes tablets.
ISO 9001:2008 certified. Manufacturing units in Daman and Dehradun. Focus on emerging markets. Troubleshooting old products. Patent non-infringing generics.
Translation:
They go where big pharma doesn’t bother.
FY24 revenue breakup:
- 91% from sale of products
- 4% from interest income
- 1% forex gains
- Remaining from other income
Geographically:
- Ethiopia: 19%
- Domestic India: 25%
- Rest of World: 56%
That’s a lot of exposure to export markets. Which means forex swings
